Connect with us

Technology

Nammi Therapeutics, Inc. Completes Series B Round with Investment from MMRF’s Myeloma Investment Fund; Advances Clinical Development of Lead Program, QXL138AM

Published

on

LOS ANGELES, Aug. 6, 2024 /PRNewswire/ — Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment Fund (MIF) in a $30M Series B financing round prior to the planned start of a first-in-human Phase 1 study of our lead program, QXL138AM, in patients with locally advanced unresectable and/or metastatic solid tumors and multiple myeloma.

QXL138AM is a Masked Immunocytokine (MIC) comprised of a masked interferon alpha (IFNa) fused to an antibody that targets the CD138 protein on the surface of the tumor cells. Once QXL138AM binds to the tumor cell, proteases on the cell surface cleave the mask off of the IFNa allowing it to bind its receptor. Activation of the IFNa receptor complex induces direct killing of tumor cells in addition to activating innate and adaptive anti-tumor immunity. Preclinical data has demonstrated significant anti-tumor efficacy across more than 10 tumor types including multiple myeloma where complete regression at doses as low as 0.1 mg/kg have been observed. Nammi has secured Orphan Drug Designation in multiple myeloma from the FDA on the strength of this data.

“While the multiple myeloma field has greatly benefitted from development of bispecific and cell therapies, there unfortunately remains a significant need for novel therapeutics such as QXL138AM.”, said David Stover, Ph.D., President and CEO of Nammi. “We are very excited to partner with MIF and the Multiple Myeloma Research Foundation (MMRF) and leverage their expertise to accelerate the development of QXL138AM. Together, we will work to realize the potential of this therapy to improve the lives of patients with multiple myeloma.”

With this investment by MIF, Nammi anticipates the $30M Series B financing round will be fully subscribed upon its closing when the first patient has been treated with QXL138AM.

“Nammi’s innovative technology and its application in multiple myeloma is an important step for the myeloma patient community,” said Michael Andreini, President and CEO of the Multiple Myeloma Research Foundation. “Advancing new therapeutic options for patients is the most critical task-at-hand, so we are thrilled to support Nammi’s Phase-1 trial to learn the potential of this exciting new immunotherapy approach.”

About Nammi Therapeutics, Inc.

Nammi Therapeutics, Inc. is an immuno-oncology company based in Los Angeles that is developing platforms and products that selectively activate anti-tumor immunity within the tumor microenvironment while minimizing systemic activation.  By reducing systemic activation of the immune system, Nammi expects to improve safety and enhance the ability to combine multiple immune modulators.  In addition to the MIC platform, Nammi has also developed a nanoparticle platform to deliver Immune Modulating Prodrugs (IMPs) using their Nammisome technology. Multiple Nammisome clinical candidates have also been selected for development. For more information visit www.nammirx.com or email info@nammirx.com  

About the Myeloma Investment Fund (MIF)

The Myeloma Investment Fund is a venture philanthropy fund that invests in promising companies, clinical assets, and technologies in oncology to drive the development of new therapies for multiple myeloma. The MIF collaborates closely with portfolio companies to help them advance multiple myeloma research. This evergreen fund is supported entirely by philanthropy; all profits will be reinvested back into research for more effective treatments until there is a cure for every patient. For more information, visit www.myelomainvestmentfund.org 

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) is the largest nonprofit in the world solely focused on accelerating a cure for each and every multiple myeloma patient. We drive the development and delivery of next-generation therapies, leverage data to identify optimal and more personalized treatment approaches and empower myeloma patients and the broader community with information and resources to extend their lives. Central to our mission is our commitment to advancing health equity so that all myeloma patients can benefit from the scientific and clinical advances we pursue. Since our inception, the MMRF has committed over $600 million for research, opened nearly 100 clinical trials, and helped bring 15+ FDA-approved therapies to market, which have tripled the life expectancy of myeloma patients. To learn more, visit www.themmrf.org 

For MMRF or MIF media inquiries, please contact: Anna Otis, Manager, Brand Marketing, otisa@themmrf.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/nammi-therapeutics-inc-completes-series-b-round-with-investment-from-mmrfs-myeloma-investment-fund-advances-clinical-development-of-lead-program-qxl138am-302215766.html

SOURCE Nammi Therapeutics, Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

DXC Technology Names Brad Novak as Chief Information Officer

Published

on

By

Veteran Technology Executive Joins DXC’s Leadership Team

ASHBURN, Va., Jan. 2, 2025 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced the appointment of Brad Novak as Chief Information Officer. Novak joins DXC’s leadership team, with a strong focus on leveraging AI throughout DXC operations. He will report to DXC’s Chief Administrative Officer, James Walker.

In this role, Novak will strategically embed AI across the infrastructure. He will also lead the team to integrate, standardize and consolidate various platforms, tools, and processes to enhance workforce productivity and operational efficiency. 

Novak is a senior technologist and brings over 30 years of experience in financial services, spanning application development, infrastructure and service management. He has worked at several global financial services firms, most recently Barclays, where he was the CTO for the Corporate and Investment Bank, leading technology architecture and strategy. Novak has also worked in Private Equity and Venture Capital, assessing investment opportunities and advising portfolio companies on their technology strategies.   

For more information DXC’s leadership team, visit here.

Forward Looking Statements

All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, and no assurance can be given that any result, goal or plan set forth in any forward-looking statement can or will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. For a written description of these factors, see the section titled “Risk Factors” in DXC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and any updating information in subsequent SEC filings. Readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, except as required by law.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.

CONTACT: Mihir Bellamkonda, Media Relations, mihir.bellamkonda@dxc.com; Roger Sachs, Investor Relations, roger.sachs@dxc.com

Photo – https://mma.prnewswire.com/media/2589628/DXC_Technology_Company_DXC_Technology_Names_Brad_Novak_as_Chief.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dxc-technology-names-brad-novak-as-chief-information-officer-302341382.html

Continue Reading

Technology

Class Action Filed Against Joint Stock Company Kaspi.kz (KSPI) – February 18, 2025 Deadline to Join – Contact The Gross Law Firm

Published

on

By

NEW YORK, Jan. 2, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Joint Stock Company Kaspi.kz (NASDAQ: KSPI).

Shareholders who purchased shares of KSPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/joint-stock-company-kaspi-kz-loss-submission-form/?id=119693&from=4 

CLASS PERIOD: January 19, 2024 to September 19, 2024

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Joint Stock Company Kaspi.kz continued doing business with Russian entities, and also providing services to Russian citizens, after Russia’s 2022 invasion of Ukraine, thereby exposing the Company to the undisclosed risk of sanctions; (2) the Company engaged in undisclosed related party transactions; (3) certain of the Company’s executives have links to reputed criminals; and (4) as a result, defendants’ statements about Joint Stock Company Kaspi.kz’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

DEADLINE: February 18, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/joint-stock-company-kaspi-kz-loss-submission-form/?id=119693&from=4 

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of KSPI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 18, 2025. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com 
Phone: (646) 453-8903

View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-joint-stock-company-kaspikz-kspi—february-18-2025-deadline-to-join–contact-the-gross-law-firm-302341315.html

SOURCE Gross Law Firm

Continue Reading

Technology

Canadian defined benefit pension plans show slightly decreased funded levels in Q4: Aon

Published

on

By

TORONTO, Jan. 2, 2025 /CNW/ — Aon plc (NYSE: AON), a leading global professional services firm, announced today that the aggregate funded ratio for Canadian pension plans in the S&P/TSX Composite Index decreased to 105.5 percent compared to 105.8 percent at the end of the third quarter, according to the Aon Pension Risk Tracker. A year ago, it was at 100.7 percent.

The Aon Pension Risk Tracker calculates the aggregate funded position on an accounting basis for companies in the S&P/TSX Composite Index with defined benefit plans. To access Aon’s interactive tracker, which dates to 2013, click here.

Key findings for the quarter ending December 31, 2024 include:

Pension assets gained 2.3 percent over the fourth quarter of 2024.The long-term Government of Canada bond yield increased 20 basis points (bps) relative to the previous quarter rate, and credit spreads narrowed by 29 bps. This combination resulted a decrease in the discount rate, from 4.42 percent to 4.33 percent.

“Most pension plans performed well in 2024, with a meaningful uptick in funded ratios,” said Nathan LaPierre, partner, Wealth Solutions, Aon. “Uncertainty is the name of the game for 2025. Many plan sponsors likely still have room to derisk and should consider doing so in light of healthy funded positions and that uncertainty.”

About Aon

Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues in over 120 countries provide our clients with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.

Follow Aon on LinkedInXFacebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.

Media Contact
Alexandre Daudelin
+1 514 967-9330

 

SOURCE Aon plc

Continue Reading

Trending